Open AccessReview
The Latest Diagnostic Imaging Technologies and AI: Applications for Melanoma Surveillance Toward Precision Oncology
by
Alessandro Valenti, Fabio Valenti, Stefano Giuliani, Simona di Martino, Luca Neroni, Cristina Sorino, Pietro Sollena, Flora Desiderio, Fulvia Elia, Maria Teresa Maccallini, Michelangelo Russillo, Italia Falcone and Antonino Guerrisi
Abstract
In recent years, the medical field has witnessed the rapid expansion and refinement of omics and imaging technologies, which have profoundly transformed patient surveillance and monitoring strategies, with stage-adapted protocols and cross-sectional imaging important in high-risk follow-up. In the melanoma context, diagnostic imaging
[...] Read more.
In recent years, the medical field has witnessed the rapid expansion and refinement of omics and imaging technologies, which have profoundly transformed patient surveillance and monitoring strategies, with stage-adapted protocols and cross-sectional imaging important in high-risk follow-up. In the melanoma context, diagnostic imaging plays a pivotal role in disease staging, follow-up and evaluation of therapeutic response. Moreover, the emergence of Artificial Intelligence (AI) has further driven the transition toward precision medicine, emphasizing the complexity and individuality of each patient: AI/Radiomics pipelines are increasingly supporting lesion characterization and response prediction within clinical workflows. Consequently, it is essential to emphasize the significant potential of quantitative imaging techniques and radiomic applications, as well as the role of AI in improving diagnostic accuracy and enabling personalized oncologic treatment. Early evidence demonstrates increased sensitivity and specificity, along with a reduction in unnecessary biopsies and imaging procedures, within selected care approaches. In this review, we will outline the current clinical guidelines for the management of melanoma patients and use them as a framework to explore and evaluate advanced imaging approaches and their potential contributions. Specifically, we compare the recommendations of major societies such as NCCN, which advocates more intensive imaging for stages IIB–IV; ESMO and AIOM, which recommend symptom-driven surveillance; and SIGN, which discourages routine imaging in the absence of clinical suspicion. Furthermore, we will describe the latest imaging technologies and the integration of AI-based tools for developing predictive models to actively support therapeutic decision-making and patient care. The conclusions will focus on the prospective role of novel imaging modalities in advancing precision oncology, improving patient outcomes and optimizing the allocation of clinical resources. Overall, the current evidences support a stage-adapted surveillance strategy (ultrasound ± elastography for lymph node regions, targeted brain MRI in high-risk patients, selective use of DECT or total-body MRI) combined with rigorously validated AI-based decision support systems to personalize follow-up, streamline workflows and optimize resource utilization.
Full article
►▼
Show Figures